{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:47:12Z","timestamp":1792514832879,"version":"4.5.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014598","name":"MannKind Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014598","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:p>Afrezza inhaled insulin offers a unique alternative to subcutaneous insulin delivery, providing a rapid onset to effectively manage postprandial glucose spikes with a short duration of action that minimizes delayed postprandial hypoglycemia. Although Afrezza has been commercially available for more than a decade, its adoption has been limited by lack of clinician awareness, confusion about dosing, and skepticism about its efficacy and safety. This article presents our perspectives on Afrezza regarding dosing and titration strategies, patient selection and education, and other practical considerations.<\/jats:p>","DOI":"10.1177\/15209156251403580","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:16:49Z","timestamp":1770005809000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dosing Afrezza: It\u2019s Not that Complicated"],"prefix":"10.1177","volume":"28","author":[{"given":"Steve V.","family":"Edelman","sequence":"first","affiliation":[{"name":"University of California San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Blevins","sequence":"additional","affiliation":[{"name":"Texas Diabetes and Endocrinology, Austin, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Parkin","sequence":"additional","affiliation":[{"name":"CGParkin Communications, Inc., Henderson, Nevada, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"University of Washington Medical School of Medicine, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816658055"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01500.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2007.0212"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2153"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.239"},{"issue":"1","key":"e_1_3_2_7_2","first-page":"A251","article-title":"A phase 1, Open-Label, randomized dose proportionality study of Technosphere\u00ae Insulin Inhalation Powder (TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects","volume":"62","author":"Baughman RA","year":"2013","unstructured":"Baughman RA, , Amin N, , Watkins E, et al. A phase 1, Open-Label, randomized dose proportionality study of Technosphere\u00ae Insulin Inhalation Powder (TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects. Diabetes, 2013; 62(Suppl. 1):A251.","journal-title":"Diabetes"},{"issue":"1","key":"e_1_3_2_8_2","first-page":"S374","article-title":"Technosphere\u00ae insulin suppresses endogenous glucose production earlier than a rapid-acting analogue (lispro) and inhaled insulin (Exubera\u00ae) [Abstract 952]","volume":"52","author":"Potocka E","year":"2009","unstructured":"Potocka E, , Hovorka R, , Baughman RA, et al. Technosphere\u00ae insulin suppresses endogenous glucose production earlier than a rapid-acting analogue (lispro) and inhaled insulin (Exubera\u00ae) [Abstract 952]. Diabetologia, 2009; 52(Suppl 1):S374.","journal-title":"Diabetologia"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0838"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0200"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14202"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2.6.1097"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0075"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0463"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60632-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000228"},{"key":"e_1_3_2_17_2","unstructured":"MannKind Corporation. Afrezza Prescribing Information. Available from: https:\/\/afrezza.com\/wp-content\/uploads\/2023\/02\/Full-Prescribing-Information-Feb-2023.pdf [Last accessed: May19 2025]."}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251403580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156251403580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251403580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:24Z","timestamp":1777400124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156251403580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":16,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2026,2,1]]}},"alternative-id":["10.1177\/15209156251403580"],"URL":"https:\/\/doi.org\/10.1177\/15209156251403580","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}